Executive to join company on September 1.
After serving as CEO for Zimmer Biomet since 2017, Bryan Hanson has been appointed as the new CEO of 3M’s Health Care Business Group. Expected to take the reins when the independent health care company is spun off from 3M, Hanson will officially join the organization on September 1.
As a separate entity, 3M believes that Health Care Business Group will be better positioned to deliver industry-leading innovation that enables better, smarter, and safer healthcare for patients worldwide.
“We are pleased to have Bryan join us to advance the spin-off of our Health Care business and build a leading independent medical technology innovation company,” said Mike Roman, 3M chairman, CEO. “His industry expertise, ability to drive growth, and track record of building a strong culture and teams will make an immediate impact.”
Reference: Bryan Hanson Named CEO of 3M’s Health Care Business Group. 3M. August 22, 2023. Accessed August 23, 2023. https://news.3m.com/Bryan-Hanson-Named-CEO-of-3Ms-Health-Care-Business-Group
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.